| Contents per vial | 5 mg |
|---|---|
| Form | Lyophilized powder |
| Packaging | Sealed glass vial |
| Purity | 99,74 % (HPLC) |
| Storage | 2–8 °C, keep dry and protect from light |
| Molecular formula | C187H291N45O59 |
| Molecular weight | 4113,58 g/mol |
| Sequence or structure | His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly |
| CAS | 910463-68-2 |
| Intended use | For laboratory research only |
About this product
Semaglutide is a long-acting analog of the GLP-1 hormone. It is mainly known for its research and clinical use in the field of type 2 diabetes and weight control. GLP-1 signaling increases satiety, reduces food intake, and promotes glucose-dependent insulin secretion. The research therefore monitors not only weight, but also glycemia and cardiometabolic risk factors.
What is SEMAGLUTIDE?
From a scientific perspective, SEMAGLUTIDE represents a substance classified as a synthetic peptide or peptide analog. Its experimental profile is mainly assessed through weight regulation, appetite control, glycemia, cardiometabolic indicators, while individual research questions can use different cell, tissue or organism models. Binding to target structures, subsequent signaling and changes in selected biological indicators are monitored.
Mechanism of action under investigation
Semaglutide activates the GLP-1 receptor. This affects the pancreatic secretion of insulin and glucagon, the satiety centers and the speed of gastric emptying.
MAIN AREAS OF RESEARCH
• Weight management: The STEP program is investigating Semaglutide in obesity and overweight, focusing on body weight, waist circumference and long-term regulation of energy intake.
• Appetite control: GLP-1 receptor activation affects satiety centers and food intake, therefore appetite regulation is an important part of Semaglutide research.
• Glycemic control: The SUSTAIN program mainly monitors HbA1c and glucose levels in type 2 diabetes, where Semaglutide supports a glucose-dependent insulin response.
• Cardiovascular outcomes: The SELECT trial directly tracked major cardiovascular events in people who were overweight or obese and had pre-existing cardiovascular disease without diabetes.
• Metabolic liver disease: Research is also devoted to steatosis and inflammatory changes of the liver, evaluating the amount of liver fat and histological indicators of the disease.
Research findings to date
Work to date with SEMAGLUTIDE is devoted to areas that include weight regulation, appetite control, glycemia, cardiometabolic indicators, metabolic liver disease. It is mainly known for its research and clinical use in the field of type 2 diabetes and weight control. The research therefore monitors not only weight, but also glycemia and cardiometabolic risk factors.
Side effects of semaglutide are well documented, mainly gastrointestinal side effects such as nausea, vomiting, diarrhea, constipation, and abdominal pain. There are also other warnings and contraindications in medical use. However, the research material is not an authorized drug and should not be used for self-medication.
